In response to present and anticipated regulatory needs for routine screening of pharmaceuticals for assessment of their neurotoxic potential, a primary tier screen for rodents, consisting of a functional observational battery (FOB) and an automated test of motor activity, has been developed at Searle. Additionally, an FOB for dogs currently is being developed. The rodent FOB assess such functions as home cage and open field activity, stimulus reactivity, and neuromuscular function. The dog FOB emphasizes evaluation of gait, postural reactions, and reflex function. The strategy taken has been to incorporate the primary rodent tier screen into repeated dose preclinical studies. Positive findings would trigger a secondary tier of testing, which would involve the use of more complex and integrated tests of neurobehavioral function. The methodologies for both rodent and nonrodent primary tier screens, validation study results, and the scientific criteria that would trigger secondary tier testing are discussed.
INTRODUCTION
NCREASING AWARENESS ON THE PART of the scientific community, regulatory agencies, and the public that I environmental chemicals, food additives, and drugs potentially can cause neurotoxicity in humans, has stimulated the need for development of testing strategies that will systematically assess neurotoxic potential. New and revised neurotoxicity guidelines have been published by the U. S . Environmental Protection Agency"' that will be used in registering new chemicals under the Federal Insecticide, Fungicide, and Rodenticide Act.
The Food and Drug Administration (FDA) , has yet to identify any formal requirement for systematic neurotoxicity testing. Present guidelines require any behavioral abnormalities to be recorded, and several sections of brain, spinal cord, and peripheral nerve to be taken for histopathological examination. In recent years, however, the FDA sponsored a study conducted by the Life Sciences Research Office (LSRO) of the Federation of American Societies for Experimental Biology (FASEB) to examine current scientific opinion and available information on the use of neurotoxicity testing in conventional test protocols. The LSRO convened an ad hoc Expert Panel who noted that there were deficiencies in study protocols, data collection methods, and identification of appropriate endpoints of neurotoxicity.'2' The Expert Panel outlined a two-tiered strategy for assessing the neurotoxic potential of pharmaceuticals. In the primary tier screen, neurobehavior would be assessed using a functional observational battery (FOB) and an automated test of motor activity. Positive findings at this level of testing would signal the need for a secondary tier of testing using more complex tests to evaluate sensory and motor function.
In recognition of the need for a more systematic approach to evaluating neurotoxic potential, a rat tier I screen (FOB and motor activity) has been developed and validated at Searle. Additionally, work is in process to develop Searle, 4901 Searle Parkway, Skokie, Illinois. a more limited primary tier screen in the dog. The methodologies, validation approaches, and strategies for testing in the framework of conventional safety assessment studies will be discussed in this report.
MATERIALS AND METHODS

Rat tier I screen
All development and validation work for the rat tier I screen in this laboratory has been undertaken using Sprague-Dawley rats (Charles River CD rats, Portage, MI). Since rats are about 35-42 days old at study start for most pivotal safety assessment studies of pharmaceuticals, this age range has been used as often as possible for the neurobehavioral work.
The laboratory conditions generally applied to rodents used in routine safety assessment studies were duplicated for animals used in the tier I development work. Animals were housed individually in stainless-steel wire mesh cages with free access to Purina Certified Chow 5002 (Purina Labs, St. Louis, MO) and city tap water. They were also maintained on a 12-h light/l2-h dark cycle in rooms that were temperature (19-25°C) and humidity (25% or greater) controlled.
The rat tier I screen developed at Searle consists of a functional observational battery (FOB) and a test of locomotor activity.
The functional observational battery (FOB) was drawn from a number of screens developed by the author and other investigator^'^"' and encompasses measures of home cage and open field activity, stimulus reactivity, as well as assessment of physiologic and neuromuscular function (Table 1) . Locomotor activity was measured in Plexiglas@ test enclosures (48.3 cm long X 26.7 cm wide X 20.3 cm deep) using a photocell detection procedure (San Diego Instruments, San Diego, CA). Three photobeams are mounted 1 1 cm apart on a rigid rectangular frame that fits over the test enclosures. The photobeams bisect each enclosure across the short axis. Events inside the test chamber are monitored by a computer-based experimental control and data acquisition system. Animal movement inside the test chamber interrupts the photobeams and is translated into activity counts.
Dog tier I screen
Development work for the dog tier I screen in this laboratory has been undertaken using Beagles (primarily obtained from Ridgland Laboratories, Mt. Horeb, WI). Dogs were housed individually in stainless-steel cages, fed once per day with Purina Certified Chow 5007 (Purina Labs, St. Louis, MO), and had free access to city tap water. Animals were maintained on a 12-h light/l2-h dark cycle in rooms that were temperature (19-25°C) and humidity (25% or greater) controlled.
The dog tier I screen consists only of a FOB which has been adapted to some extent both from the rat FOB and from the typical physical and neurological examinations conducted in dogs. In this screen, there are elements of home cage and open field activity, as well as postural reactions and reflex activity ( Table 2) .
RESULTS
Rat tier I screen validation approaches
Pharmacological Agents. Validation studies have been conducted in order to assess the validity, sensitivity, and specificity of the tier I screen developed in this laboratory. The first approach to validating the rat screen was to determine the profiles of effects obtained with a number of centrally acting pharmacological agents (such as stimulants, depressants, sedative hypnotics, and tremorigenic agents). Examples of the profiles obtained with three such compounds, namely amphetamine, chlorpromazine, and ethanol (only FOB data), are discussed below.
Amphetamine. Amphetamine was administered intrapentoneally at doses of 0,0.75, 1.5, and 3.0 mg/kg, and testing began 30 minutes later. A summary of the profile of effects obtained using the FOB is shown in Table 3 , and locomotor activity data are in Table 4 . An increased occurrence of open field rearing, stereotypy (characterized by head bobbing, weaving, and excessive sniffing), tiptoe walking, and arousal were seen at all doses of 
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Approach response: Approach rat head on with blunt object held - Reduced hindlimb resistance, animal shows some weakness 3 = Hindlimb resistance is present 2. Grip Strength (Kg): Measure forelimb and hindlimb grip strength using a device similar to that of Meyer et al., 1979.7 Allow the animal to grip a triangular bar with its forepaws and pull it gently backwards along a platform until its grip is broken. As the backward locomotion continues, the animal's hindpaws will reach a T-shaped rearlimb bar which it will grasp and be forced to release by continued pulling. Forelimb and hindlimb grip strength will be measured using Chatillon push-pull strain gauges (J.A. King, Greensboro, NC). The average of three valid measurements will be taken for each rat. amphetamine. Animals from the 1.5 and 3.0 mg/kg groups also showed increases in home cage rearing, and occurrence of piloerection. Increased reactivity to touch (3.0 mg/kg) and finger snap (all dose groups) also was observed. Locomotor activity was significantly increased (relative to control) in the 1.5 and 3.0 mglkg groups (a nonsignificant increase was also seen in the 0.75 mg/kg females). Locomotor activity did not, however, increase in a dose-related manner; this was attributed to a progressive increase in the intensity and occurrence of stereotypy with increasing doses of amphetamine, which resulted in a disruption of ambulatory movement.
Chlorpromazine. Animals received chlorpromazine (0, 1 .O, 3.0, and 5.0 mg/kg intraperitoneally), and behavioral testing began 45 minutes later. A summary of FOB and locomotor activity results are shown in Tables  5 and 6 , respectively. Findings such as decreased open field rearing, rotarod performance, and body temperature, as well as increased foot splay occurred in a dose-related manner. Other functional changes included decreased reactivity to removal from the cage and handling (3.0 and 5.0 mg/kg), slight to total impairment of mobility (3.0 and 5.0 mg/kg), decreased forelimb grip strength (5 mg/kg), increased occurrence of catalepsy (5.0 mg/kg), and ptosis (5 .O mg/kg). Locomotor activity significantly decreased in a dose-related manner for both sexes.
Ethanol. Rats received a single dose of ethanol (0, 0.5, 1.25, or 2.0 gkg) by gavage, and testing began 15 minutes later. A summary of the FOB findings is shown in Table 7 . A dosage-related decrease was seen in rotarod performance and body temperature. Other changes included a decrease in hindlimb grip strength (0.5, 1.25, and 2.5 g/kg), decreased reactivity to removal from the home cage and handling (1.25 and 2.0 g/kg), and an increased For the second phase of validation, the effects of a series of chemically related neurotoxic agents (such as alkyltins and organophosphates) were examined in the framework of repeated dose studies (with reversal phases) in order to determine the utility of the tier I screen in identifying dose response and time course relationships. Results from one such study using trimethyl tin are discussed below.
Trimethyl Tin. In this study, rats of both sexes (15/sexes/group) received daily dosages by gavage of 0, 0.4, 0.75, and 1.5 mg/kg TMT over a 22-day period.'*' Ten per gender per group were sacrificed and necropsied at the end of dosing, while the remainder were sacrificed and necropsied at the end of a two-week reversal period. bValues are means k SD.
'Significantly different from control (p < 0.05).
A summary of the effects observed in this study are shown in Table 8 . The data for the 1.5 mg/kg animals are not included in the table, since all animals exhibited marked systemic toxicity and died or were sacrificed in extremis during the treatment phase. The nature and progression of the effects seen in the 0.75 mg/kg group are consistent with those previously reported in the rat after acute exposure to trimethyl tin.'" There was a progressive increase in rearing and motor activity during weeks 1 to 2 in the 0.75 mg/kg animals, followed by a period of increased reactivity to handling and various stimuli, finally progressing to convulsions (and in some cases, death) in a number of animals during the reversal period. While this syndrome was not seen in the 0.4 mg/kg animals, some of the rats from this dose group showed signs of increased motor activity and tremors during week 3 of dosing. Neuropathological changes were dose related and included neuronal necrosis of the olefactory and entorhinal cortices, hippocampus and dentate g y m .
Validation of dog tier I dog screen
Validation work for the dog tier I screen is at a much more preliminary stage of development than the rat screen. Most of the effort up to this time has been directed toward gathering data in normal untreated animals and fine tuning the test measures. Difficulties associated with conducting behavioral testing of this type in the dog are its size (typical Beagles used in this laboratory are in the range of 7-12 kg), the degree to which the animal will cooperate, and interactions of the animal with the experimenter which can confound interpretation of data. Validation work has been initiated in the dog using ethanol (administered acutely by gavage at doses of 0.7, 1.4, and 2.1 glkg). The results obtained so far indicate that ethanol has effects on several test measures such as time to first step (increased), forelimb placement (slight to total impairment), and proprioceptive positioning (slight to moderate impairment). It should be noted that the remainder of the validation work with the dog will be confined only to the use of pharmacological agents.
Strategy for testing
A suggested strategy for neurobehavioral screening of pharmaceuticals in rats is shown in Table 9 . Using this strategy, the tier I screen would be incorporated into most or all oral 13-week safety assessment studies. The 13-week study is suggested because it is of sufficient length to clearly define a subchronic neurotoxic effect, and in many cases, is the first pivotal study to include a reversal period. Positive tier 1 findings such as defined patterns of behavioral change that are dose and/or time related, evidence of neuropathology, or both, would flag the compound as having some neurotoxic potential. At this point, a more complex level of tier I1 testing would need to be designed, depending on the profile of observed effects, in order to further characterize and confirm tier I findings.
DISCUSSION
Two approaches to validation of tier I screens have been described. For the first approach, profiles of effects were obtained at time of peak effect for several centrally acting pharmacological agents. The profiles obtained for amphetamine (a sympathomimetic amine), chlorpromazine (a neuroleptic), and ethanol are consistant with the behavioral/functional effects that have been reported in the literature for these compounds.'1°-'2' This type of validation data has been of value both for comparative (when evaluating the results of tier I testing of new compounds) and training purposes.
In the subacute trimethyl tin study, it was possible, using the tier I screen, to detect the development of a behavioral syndrome similar to that seen in rodents and, to some extent, in human^.'^.'^' Additionally, the observed neuropathological changes seen in the present study are consistent with those reported in the literat~re."~"~' While significant mortality occurred in the 0.75 mgikg dose after 3 weeks of exposure, in another study in this laboratory where trimethyl tin was given daily at a dose of 1 .O mg/kg over a 2-week period, no animals died either during the dosing or during the reversal phase of the study.'I6' These data, along with the behavioral findings of the subacute study, suggest that duration of exposure plays an important role in the expression of the toxicity induced by trimethyl tin, and that a cumulative threshold dose needs to be achieved before systemic and behavioral toxicity is observed. It should be noted that there is some question as to whether all pharmaceuticals in development should be tested in the tier I screen or just those known to have therapeutic effects on the nervous system. While most candidate pharmacological compounds usually undergo some CNS screening early in development, this type of testing is usually acute in nature, uses a limited range of doses, and may not be able to detect a more subtle neurobehavioral effect. Thus, the risk of using a selective screening approach for Tier I testing is that meaningful neurobehavioral findings elicited by non CNS/PNS drugs could be missed. Consideration also needs to be given as to whether it is feasible or practical to test animals in the tier I screen when novel routes of administration, such as topical or continuous intravenous infusion, are being used.
In conclusion, the validation work done with both pharmacological agents and known neurotoxins indicates that the tier I screen developed in this laboratory is capable of identifying predicted neurobehavioral/functional effects in the rat.
